ArticleChildren (Basel, Switzerland)2025
Pediatric-Onset Multiple Sclerosis in Tyrol, Austria: Epidemiology, Clinical Profile and Treatment Patterns from a Single Center (2015-2024).
Article in Children (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesPediatric-onset multiple sclerosis (POMS) accounts for 3-10% of all multiple sclerosis (MS) cases and represents the earliest manifestation of chronic autoimmune demyelination of the central nervous system. While increasing incidence rates have been reported in Europe, no regional data exist for Austria. This study aimed to determine the incidence, prevalence, and clinical characteristics of POMS in Tyrol, Austria, over a 10-year period.
methodsAll patients diagnosed with MS before 18 years of age between 1 January 2015 and 31 December 2024, were included. Diagnoses were confirmed according to the 2010 and 2017 McDonald criteria and re-evaluated using the 2024 revisions. Demographic, clinical, cerebrospinal fluid (CSF), and MRI data were systematically reviewed. Incidence and prevalence rates were calculated with 95% confidence intervals (CI) using the exact Clopper-Pearson method.
resultsTwenty-nine patients were newly diagnosed with POMS (26 female; median age 15 years, range 11-17), corresponding to a pooled 10-year incidence of 2.19 per 100,000 person-years (95% CI 1.47-3.14) and a point prevalence of 6.7 per 100,000 children (95% CI 3.1-12.8) as of 31 December 2024. Sensory (55%) and visual (31%) symptoms predominated at onset. Pleocytosis was found in 93%, and all CSF samples showed positive oligoclonal bands. MRI revealed supratentorial lesions in 97%, infratentorial in 69%, and spinal in 73%. The median annualized relapse rate was 0.67, and all patients had an EDSS of 0 at last follow-up.
conclusionsThis first regional analysis of pediatric-onset MS in Austria demonstrates a higher incidence than most previously reported European cohorts, positioning Tyrol within the upper European range. The findings highlight the impact of early recognition, structured diagnostics, and timely initiation of disease-modifying therapy on favorable short-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.